Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats

Cancer Biology and Therapy

Volumn 11, Issue 7, 2011, Pages 671-677

  Prisciandaro, Luca D ^a,b,c   Geier, Mark S ^a,d   Butler, Ross N ^a,e   Cummins, Adrian G ^c   Howarth, Gordon S ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

^d SOUTH AUSTRALIAN RESEARCH AND DEVELOPMENT INSTITUTE   (Australia)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Escherichia coli nissle 1917; Intestinal mucositis; Lactobacillus fermentum BR11; Probiotic supernatants; Soluble factors

Indexed keywords

FLUOROURACIL; MYELOPEROXIDASE; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYPT CELL; DARK AGOUTI RAT; ESCHERICHIA COLI; FEMALE; INTESTINE MUCOSA; INTESTINE MUCOSITIS; INTESTINE VILLUS; JEJUNUM; LACTOBACILLUS FERMENTUM; MUCOSA INFLAMMATION; NONHUMAN; RAT; SUPERNATANT; TISSUE INJURY;

ANIMALS; ENZYME ACTIVATION; FEMALE; FLUOROURACIL; INTESTINAL MUCOSA; INTESTINE, SMALL; MUCINS; MUCOSITIS; PEROXIDASE; PROBIOTICS; RATS; SEVERITY OF ILLNESS INDEX; SUCRASE;

EID: 79953331208     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.7.14896     Document Type: Article

References (49)

1. Fata F, Ron IG, Kemeny N, O'Reilly E, Klimstra D, Kelsen DP. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 1999; 86:1129-34.
2. Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M, Schlag PM. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer 1999; 35:202-7. (Pubitemid 29136768)
3. Soares PM, Mota JM, Gomes AS, Oliveira RB, Assreuy AM, Brito GA, et al. Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. Cancer Chemother Pharmacol 2008; 63:91-8.
4. Daniele B, Secondulfo M, De Vivo R, Pignata S, De Magistris L, Delrio P, et al. Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. J Clin Gastroenterol 2001; 32:228-30. (Pubitemid 32174115)
5. Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther 2003; 18:853-74. (Pubitemid 37346671)
6. Haenel H. Human normal and abnormal gastrointestinal flora. Am J Clin Nutr 1970; 23:1433-9.
7. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004; 47:1519-25. (Pubitemid 39295882)
8. Gall L. Normal fecal flora of man. Am J Clin Nutr 1970; 23:1457-65.
9. Stringer AM, Gibson RJ, Bowen JM, Logan RM, Yeoh AS, Keefe DM. Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 2007; 5:259-67. (Pubitemid 46995361)
10. van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 2010; 6:1000879.
11. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics and prebiotics. Gastroenterology 2004; 126:1620-33. (Pubitemid 38649878)
12. Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007; 115:1-11. (Pubitemid 46349312)
13. Caplan MS. Probiotic and prebiotic supplementation for the prevention of neonatal necrotizing enterocolitis. J Perinatol 2009; 29:2-6.
14. Kopp MV, Salfeld P. Probiotics and prevention of allergic disease. Curr Opin Clin Nutr Metab Care 2009; 12:298-303.
15. Tursi A, Papagrigoriadis S. Review article: the current and evolving treatment of colonic diverticular disease. Aliment Pharmacol Ther 2009; 30:532-46.
16. Zanello G, Meurens F, Berri M, Salmon H. Saccharomyces boulardii effects on gastrointestinal diseases. Curr Issues Mol Biol 2009; 11:47-58.
17. Prisciandaro L, Geier M, Butler R, Cummins A, Howarth G. Probiotics and their derivatives as treatments for inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:1906-14.
18. Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2008; 294:1060-9.
19. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105:16731-6.
20. Zidek Z, Kmonickova E, Kostecka P, Tlaskalova-Hogenova H. Decisive role of lipopolysaccharide in activating nitric oxide and cytokine production by the probiotic Escherichia coli strain Nissle 1917. Folia Microbiol (Praha) 2010; 55:181-9.
21. Watanabe T, Nishio H, Tanigawa T, Yamagami H, Okazaki H, Watanabe K, et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 2009; 297:506-13.
22. Jensen GS, Benson KF, Carter SG, Endres JR. GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC Immunol 2010; 11:15.
23. Geier MSR, Butler N, Giffard PM, Howarth GS. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. Int J Food Microbiol 2007; 114:267-74. (Pubitemid 46283086)
24. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck 2003; 25:1057-70. (Pubitemid 37475269)
25. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34:39-43. (Pubitemid 28210529)
26. Arribas B, Rodriguez-Cabezas ME, Camuesco D, Comalada M, Bailon E, Utrilla P, et al. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol 2009; 157:1024-33.
27. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE 2007; 2:1308.
28. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007; 9:804-16.
29. Mauger CA, Butler RN, Geier MS, Tooley KL, Howarth GS. Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. Dig Dis Sci 2007; 52:612-9.
30. Borthakur A, Gill RK, Tyagi S, Koutsouris A, Alrefai WA, Hecht GA, et al. The probiotic Lactobacillus acidophilus stimulates chloride/hydroxyl exchange activity in human intestinal epithelial cells. J Nutr 2008; 138:1355-9. (Pubitemid 351931002)
31. Roselli M, Finamore A, Britti MS, Mengheri E. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br J Nutr 2006; 95:1177-84. (Pubitemid 43985998)
32. Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007; 75:2399-407.
33. Howarth GS. Probiotic-derived factors: probiotaceuticals? J Nutr 2010; 140:229-30.
34. Hung J, Cooper D, Turner MS, Walsh T, Giffard PM. Cystine uptake prevents production of hydrogen peroxide by Lactobacillus fermentum BR11. FEMS Microbiol Lett 2003; 227:93-9. (Pubitemid 41123326)
35. Hung J, Turner MS, Walsh T, Giffard PM. BspA (CyuC) in Lactobacillus fermentum BR11 is a highly expressed high-affinity L-cystine-binding protein. Curr Microbiol 2005; 50:33-7. (Pubitemid 40655426)
36. Barth S, Duncker S, Hempe J, Breves G, Baljer G, Bauerfeind R. Escherichia coli Nissle 1917 for probiotic use in piglets: evidence for intestinal colonization. J Appl Microbiol 2009; 107:1697-710.
37. Guzy C, Paclik D, Schirbel A, Sonnenborn U, Wiedenmann B, Sturm A. The probiotic Escherichia coli strain Nissle 1917 induces gammadelta T cell apoptosis via caspase- and FasL-dependent pathways. Int Immunol 2008; 20:829-40.
38. Otte JM, Mahjurian-Namari R, Brand S, Werner I, Schmidt WE, Schmitz F. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr Cancer 2009; 61:103-13.
39. Stringer AM, Gibson RJ, Bowen JM, Keefe DM. Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 2009; 10:79-83.
40. Kamada N, Maeda K, Inoue N, Hisamatsu T, Okamoto S, Hong KS, et al. Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infect Immun 2008; 76:214-20.
41. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 2006; 74:4075-82.
42. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Hamilton J, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 2009; 234:430-41.
43. Caballero-Franco C, Keller K, De Simone C, Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007; 292:315-22.
44. Kim Y, Kim SH, Whang KY, Kim YJ, Oh S. Inhibition of Escherichia coli O157:H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J Microbiol Biotechnol 2008; 18:1278-85.
45. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM, Coran AG. Probiotics upregulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 2002; 18:586-90. (Pubitemid 36069911)
46. Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996; 126:2519-30. (Pubitemid 26339666)
47. Cool JC, Dyer JL, Xian CJ, Butler RN, Geier MS, Howarth GS. Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Horm IGF Res 2005; 15:72-82. (Pubitemid 40220858)
48. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87:1344-50.
49. Forder RE, Howarth GS, Tivey DR, Hughes RJ. Bacterial modulation of small intestinal goblet cells and mucin composition during early posthatch development of poultry. Poult Sci 2007; 86:2396-403. (Pubitemid 350097225)